Highlights

  • Pacific Edge reported a 2.7% QoQ increase in total test volumes to 5,582 in Q4 FY26.
  • Strong progress in U.S. insurance coverage and Asia-Pacific adoption boosted commercial momentum.
  • Growing optimism around a potential Medicare policy shift following positive expert panel feedback.

Pacific Edge Limited (NZX:PEB) reported steady operational progress in Q4 FY26, with total laboratory throughput rising 2.7% quarter-on-quarter to 5,582 tests. The growth reflects increasing adoption of its Cxbladder diagnostic portfolio despite ongoing commercial and operational challenges. Momentum was supported by expanding insurance coverage in the United States and rising utilisation across the Asia-Pacific region. Importantly, the company highlighted strong backing from clinical experts during a key advisory panel review, reinforcing expectations of a favourable Medicare policy update in the coming quarters.

While U.S. growth remained modest due to limited coverage and external disruptions, Asia-Pacific delivered stronger gains driven by both clinical and commercial demand. The company also improved sales efficiency despite a reduced workforce. Overall, the quarter signals strengthening fundamentals and positions Pacific Edge for a potential inflection point as regulatory and reimbursement tailwinds continue to build.

What’s Driving Growth in Test Volumes?

Growth in test volumes during Q4 FY26 was driven by a combination of improving global demand and expanding clinical adoption. In the United States, Pacific Edge saw a modest 1% increase in volumes, supported primarily by higher utilisation within large healthcare networks. Meanwhile, the Asia-Pacific region delivered stronger growth of 7.7%, reflecting increased commercial uptake and participation in clinical studies.

New hospital partnerships and broader integration of Cxbladder tests into patient care also contributed to rising volumes. Despite challenges such as fewer operating days and product transition in the U.S., the company maintained upward momentum, highlighting resilience in demand and growing acceptance of its diagnostic solutions across key markets.

How Are Policy and Commercial Wins Shaping the Outlook?

Policy developments and commercial expansion are playing a crucial role in shaping the future outlook for Pacific Edge. Strong endorsement from a clinical advisory panel has increased confidence in a positive Medicare coverage decision, which could significantly expand access in the U.S. market. At the same time, the company secured important wins with major insurers, improving reimbursement coverage for its key products.

Expansion into leading hospitals across Asia-Pacific further strengthens its global footprint. Although the company reduced its sales force as part of cost-control measures, it achieved higher efficiency, indicating a more focused commercial strategy. These combined factors suggest that Pacific Edge is building momentum toward a potential turning point in both revenue growth and market penetration.